Stockscreener 앱 받기
6.22
0.96%
-0.06
시간 외 거래:
5.91
-0.31
-4.98%
전일 마감가:
$6.28
열려 있는:
$6.04
하루 거래량:
1.06M
Relative Volume:
0.57
시가총액:
$601.36M
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-21.45
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
-4.67%
1개월 성능:
+46.01%
6개월 성능:
+105.96%
1년 성능:
+96.84%
1일 변동 폭
$5.8505
$6.245
1주일 범위
$5.6501
$6.68
52주 변동 폭
$2.30
$7.39
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.22 | 601.36M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Longview News-Journal
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
Leerink Partnrs Has Optimistic Outlook of TRVI Q1 Earnings - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey
Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World
HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World
D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider
B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing Promising Trials - GuruFocus
Trevi Therapeutics Advances Haduvio in Clinical Trials - TipRanks
Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results - Investing.com
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PR Newswire
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study - MSN
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week - Yahoo Finance
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Analysts Increase Earnings Estimates for TRVI - Defense World
Stock Traders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - The AM Reporter
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World
Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - The Malaysian Reserve
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer - TipRanks
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond James - Defense World
Needham & Company LLC Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World
Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Kilgore News Herald
Trevi Therapeutics stock soars to 52-week high of $6.58 By Investing.com - Investing.com Australia
Trevi Therapeutics reports positive Phase 2a trial results - Investing.com India
Trevi Therapeutics reports positive Phase 2a trial results By Investing.com - Investing.com South Africa
Trevi Therapeutics Just Got a 212% Price Target Bump – Here’s Why - Wall Street Pit
Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: MOA, ROA, - openPR
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):